Table 3.

Correlation with clinicopathologic characteristics of the patients and immunostaining of ANXA4 and FLNA (n = 94)

	Cases	ANXA4 (+)(%)	p value	FLNA (+)(%)	p value
Gender
Male	83	59(71.1)	0.455	57(68.7)	0.425
Female	11	9(81.8)		5(45.5)
Age
≤40 yr	42	32(76.2)	0.453	28(66.7)	0.896
>40 yr	52	36(69.2)		34(65.4)
T stage
T1	8	3(37.5)	0.017*	2(25)	0.042*
T2	44	29(65.9)		28(63.6)
T3	36	30(83.3)		27(75)
T4	6	6(100)		5(83.3)
N Stage
N0	48	27(56.3)	0.001*	38(79.2)	0.017*
N1	43	38(88.4)		23(53.5)
N2	3	3(100)		1(33.3)
UICC Stage
I	7	2(28.6)	0.004*	4(57.1)	0.696
II	31	19(61.3)		19(61.3)
III	50	41(82)		34(68)
IV	6	6(100)		5(83.3)
Diff.
Well	80	59(73.8)	0.652	55(68.8)	0.180
Moderate	10	6(60)		6(60)
Poor	4	3(75)		1(25)
OSF Stage
Early	27	22(81.5)	0.294	16(59.3)	0.278
Moderated	46	30(65.2)		34(73.9)
Advanced	21	16(76.2)		12(57.1)

^{* P < 0.05}